Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 356 entries
Sorted by: Best Match Show Resources per page
Pharmacotherapy for treatment-resistant schizophrenia.

Neuropsychiatric disease and treatment

McIlwain ME, Harrison J, Wheeler AJ, Russell BR.
PMID: 21552316
Neuropsychiatr Dis Treat. 2011;7:135-49. doi: 10.2147/NDT.S12769. Epub 2011 Mar 17.

Schizophrenia is a disabling mental illness with a lifetime prevalence of 0.7% worldwide and significant, often devastating, consequences on social and occupational functioning. A range of antipsychotic medications are available; however, suboptimal therapeutic response in terms of psychotic symptoms...

Cite
McIlwain ME, Harrison J, Wheeler AJ, et al. Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat. 2011;7:135-49doi: 10.2147/NDT.S12769.
McIlwain, M. E., Harrison, J., Wheeler, A. J., & Russell, B. R. (2011). Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatric disease and treatment, 7135-49. https://doi.org/10.2147/NDT.S12769
McIlwain, Meghan E, et al. "Pharmacotherapy for treatment-resistant schizophrenia." Neuropsychiatric disease and treatment vol. 7 (2011): 135-49. doi: https://doi.org/10.2147/NDT.S12769
McIlwain ME, Harrison J, Wheeler AJ, Russell BR. Pharmacotherapy for treatment-resistant schizophrenia. Neuropsychiatr Dis Treat. 2011;7:135-49. doi: 10.2147/NDT.S12769. Epub 2011 Mar 17. PMID: 21552316; PMCID: PMC3083987.
Copy Download .nbib Format: NLM
ACP Journal Club. Both typical and atypical antipsychotic agents were associated with increased risk for sudden cardiac death.

Annals of internal medicine

Marder S.
PMID: 19687486
Ann Intern Med. 2009 Aug 18;151(4):JC2-12. doi: 10.7326/0003-4819-151-4-200908180-02012.

No abstract available.

Cite
Marder S. ACP Journal Club. Both typical and atypical antipsychotic agents were associated with increased risk for sudden cardiac death. Ann Intern Med. 2009;151(4):JC2-12doi: 10.7326/0003-4819-151-4-200908180-02012.
Marder, S. (2009). ACP Journal Club. Both typical and atypical antipsychotic agents were associated with increased risk for sudden cardiac death. Annals of internal medicine, 151(4), JC2-12. https://doi.org/10.7326/0003-4819-151-4-200908180-02012
Marder, Steven. "ACP Journal Club. Both typical and atypical antipsychotic agents were associated with increased risk for sudden cardiac death." Annals of internal medicine vol. 151,4 (2009): JC2-12. doi: https://doi.org/10.7326/0003-4819-151-4-200908180-02012
Marder S. ACP Journal Club. Both typical and atypical antipsychotic agents were associated with increased risk for sudden cardiac death. Ann Intern Med. 2009 Aug 18;151(4):JC2-12. doi: 10.7326/0003-4819-151-4-200908180-02012. PMID: 19687486.
Copy Download .nbib Format: NLM
Treatment of depressive symptoms with quetiapine.

Expert review of neurotherapeutics

Kasper S.
PMID: 19810926
Expert Rev Neurother. 2003 Jul;3(4):417-23. doi: 10.1586/14737175.3.4.417.

Depressive symptoms are a frequent component of schizophrenia and other psychotic illnesses. The treatment of psychoses with conventional (typical) antipsychotic agents may worsen depressive symptoms and many patients only partially respond to treatment. Typical antipsychotics are also associated with...

Cite
Kasper S. Treatment of depressive symptoms with quetiapine. Expert Rev Neurother. 2003;3(4):417-23doi: 10.1586/14737175.3.4.417.
Kasper, S. (2003). Treatment of depressive symptoms with quetiapine. Expert review of neurotherapeutics, 3(4), 417-23. https://doi.org/10.1586/14737175.3.4.417
Kasper, Siegfried. "Treatment of depressive symptoms with quetiapine." Expert review of neurotherapeutics vol. 3,4 (2003): 417-23. doi: https://doi.org/10.1586/14737175.3.4.417
Kasper S. Treatment of depressive symptoms with quetiapine. Expert Rev Neurother. 2003 Jul;3(4):417-23. doi: 10.1586/14737175.3.4.417. PMID: 19810926.
Copy Download .nbib Format: NLM
IBZM-SPECT imaging of dopamine D(2) receptors with typical and atypical antipsychotics.

European psychiatry : the journal of the Association of European Psychiatrists

Kasper S, Tauscher J, Küfferle E, Hesselmann B, Barnas C, Brücke T.
PMID: 19698668
Eur Psychiatry. 1998;13:9s-14s.

Considerable progress has been achieved over the past 15 years in uncovering the biological basis of major psychiatric disorders. Since psychopharmacological treatment is thought to act on the underlying biological basis of the disease, brain imaging techniques enable us...

Cite
Kasper S, Tauscher J, Küfferle E, et al. IBZM-SPECT imaging of dopamine D(2) receptors with typical and atypical antipsychotics. Eur Psychiatry. 1998;13:9s-14s
Kasper, S., Tauscher, J., Küfferle, E., Hesselmann, B., Barnas, C., & Brücke, T. (1998). IBZM-SPECT imaging of dopamine D(2) receptors with typical and atypical antipsychotics. European psychiatry : the journal of the Association of European Psychiatrists, 139s-14s.
Kasper, S, et al. "IBZM-SPECT imaging of dopamine D(2) receptors with typical and atypical antipsychotics." European psychiatry : the journal of the Association of European Psychiatrists vol. 13 (1998): 9s-14s.
Kasper S, Tauscher J, Küfferle E, Hesselmann B, Barnas C, Brücke T. IBZM-SPECT imaging of dopamine D(2) receptors with typical and atypical antipsychotics. Eur Psychiatry. 1998;13:9s-14s. PMID: 19698668.
Copy Download .nbib Format: NLM
Frequency of the antipsychotic therapy acute side effects in the treatment of acute psychosis.

Bosnian journal of basic medical sciences

Loga-Zec S, Zulić I, Mulabegović N, Cerić I, Loga S, Fiseković S, Kusturica J, Krosnjar S.
PMID: 16212562
Bosn J Basic Med Sci. 2002 Dec;2(1):16-28. doi: 10.17305/bjbms.2002.3577.

Antipsychotic drugs produce a wide spectrum of physiological actions. Some of these effects differ among the various classes of antipsychotics. This medications have indications in the treatment of acute psychotic disorders. The main goal of this investigation was to...

Cite
Loga-Zec S, Zulić I, Mulabegović N, et al. Frequency of the antipsychotic therapy acute side effects in the treatment of acute psychosis. Bosn J Basic Med Sci. 2002;2(1):16-28doi: 10.17305/bjbms.2002.3577.
Loga-Zec, S., Zulić, I., Mulabegović, N., Cerić, I., Loga, S., Fiseković, S., Kusturica, J., & Krosnjar, S. (2002). Frequency of the antipsychotic therapy acute side effects in the treatment of acute psychosis. Bosnian journal of basic medical sciences, 2(1), 16-28. https://doi.org/10.17305/bjbms.2002.3577
Loga-Zec, Svjetlana, et al. "Frequency of the antipsychotic therapy acute side effects in the treatment of acute psychosis." Bosnian journal of basic medical sciences vol. 2,1 (2002): 16-28. doi: https://doi.org/10.17305/bjbms.2002.3577
Loga-Zec S, Zulić I, Mulabegović N, Cerić I, Loga S, Fiseković S, Kusturica J, Krosnjar S. Frequency of the antipsychotic therapy acute side effects in the treatment of acute psychosis. Bosn J Basic Med Sci. 2002 Dec;2(1):16-28. doi: 10.17305/bjbms.2002.3577. PMID: 16212562.
Copy Download .nbib Format: NLM
Efficacy and tolerability of aripiprazole in patients with schizophrenia & schizoaffective disorders.

Indian journal of psychiatry

Chavda RK, Laxmi L, Nair BS, Gandewar K.
PMID: 21408042
Indian J Psychiatry. 2004 Apr;46(2):150-5.

Before the 1990s, treatment of psychoses centred on conventional agents whose tolerability was limited by extrapyramidal symptoms (EPS). The past decade has seen the emergence of newer generation of antipsychotic agents. These agents provide better negative symptom efficacy, less...

Cite
Chavda RK, Laxmi L, Nair BS, et al. Efficacy and tolerability of aripiprazole in patients with schizophrenia & schizoaffective disorders. Indian J Psychiatry. 2004;46(2):150-5
Chavda, R. K., Laxmi, L., Nair, B. S., & Gandewar, K. (2004). Efficacy and tolerability of aripiprazole in patients with schizophrenia & schizoaffective disorders. Indian journal of psychiatry, 46(2), 150-5.
Chavda, R K, et al. "Efficacy and tolerability of aripiprazole in patients with schizophrenia & schizoaffective disorders." Indian journal of psychiatry vol. 46,2 (2004): 150-5.
Chavda RK, Laxmi L, Nair BS, Gandewar K. Efficacy and tolerability of aripiprazole in patients with schizophrenia & schizoaffective disorders. Indian J Psychiatry. 2004 Apr;46(2):150-5. PMID: 21408042; PMCID: PMC2949931.
Copy Download .nbib Format: NLM
The assessment and management of treatment-resistant schizophrenia in perspective.

European psychiatry : the journal of the Association of European Psychiatrists

Meltzer H, Hippius H.
PMID: 19698381
Eur Psychiatry. 1995;10:3s-5s. doi: 10.1016/0767-399x(96)80077-0.

Consensus was reached on the five following points: (1) "Treatment resistance" is a term which is widely used, but not adequately defined. In particular, definitions of "responders" and "non-responders" need to be more precise. (2) There is a need...

Cite
Meltzer H, Hippius H. The assessment and management of treatment-resistant schizophrenia in perspective. Eur Psychiatry. 1995;10:3s-5sdoi: 10.1016/0767-399x(96)80077-0.
Meltzer, H., & Hippius, H. (1995). The assessment and management of treatment-resistant schizophrenia in perspective. European psychiatry : the journal of the Association of European Psychiatrists, 103s-5s. https://doi.org/10.1016/0767-399x(96)80077-0
Meltzer, H, and Hippius, H. "The assessment and management of treatment-resistant schizophrenia in perspective." European psychiatry : the journal of the Association of European Psychiatrists vol. 10 (1995): 3s-5s. doi: https://doi.org/10.1016/0767-399x(96)80077-0
Meltzer H, Hippius H. The assessment and management of treatment-resistant schizophrenia in perspective. Eur Psychiatry. 1995;10:3s-5s. doi: 10.1016/0767-399x(96)80077-0. PMID: 19698381.
Copy Download .nbib Format: NLM
Attitudes towards taking Medicine among those patients who either received Olanzapine or First Generation Antipsychotic Agents.

Indian journal of psychiatry

Chengappa NR, Parepally H, Brar JS, Gopalani A, Chalasani L, Bear J, Levine J.
PMID: 21206845
Indian J Psychiatry. 2003 Jul;45(3):151-4.

This project evaluated the attitudes of psychiatric patients towards receiving either olanzapine or the first-generation antipsychotic agents. Newly admitted patients to a state psychiatric hospital who were either prescribed olanzapine (n=35) or other first-generation antipsychotic agents (n=34) were compared...

Cite
Chengappa NR, Parepally H, Brar JS, et al. Attitudes towards taking Medicine among those patients who either received Olanzapine or First Generation Antipsychotic Agents. Indian J Psychiatry. 2003;45(3):151-4
Chengappa, N. R., Parepally, H., Brar, J. S., Gopalani, A., Chalasani, L., Bear, J., & Levine, J. (2003). Attitudes towards taking Medicine among those patients who either received Olanzapine or First Generation Antipsychotic Agents. Indian journal of psychiatry, 45(3), 151-4.
Chengappa, N R, et al. "Attitudes towards taking Medicine among those patients who either received Olanzapine or First Generation Antipsychotic Agents." Indian journal of psychiatry vol. 45,3 (2003): 151-4.
Chengappa NR, Parepally H, Brar JS, Gopalani A, Chalasani L, Bear J, Levine J. Attitudes towards taking Medicine among those patients who either received Olanzapine or First Generation Antipsychotic Agents. Indian J Psychiatry. 2003 Jul;45(3):151-4. PMID: 21206845; PMCID: PMC2952159.
Copy Download .nbib Format: NLM
[Neuroleptic malignant syndrome and atypical antipsychotics: two case reports].

Psychiatrike = Psychiatriki

Andreou C, Bozikas V, Koumenis G, Garyfallos G, Giouzepas I, Fokas K.
PMID: 22466631
Psychiatriki. 2007 Jul;18(3):273-6.

Neuroleptic malignant syndrome (NMS) constitutes the most serious adverse effect of antipsychotic medications. Although it was initially described as a complication of conventional neuroleptics, atypical antipsychotic agents are also capable of inducing the syndrome. It has been suggested that...

Cite
Andreou C, Bozikas V, Koumenis G, et al. [Neuroleptic malignant syndrome and atypical antipsychotics: two case reports]. Psychiatriki. 2007;18(3):273-6
Andreou, C., Bozikas, V., Koumenis, G., Garyfallos, G., Giouzepas, I., & Fokas, K. (2007). [Neuroleptic malignant syndrome and atypical antipsychotics: two case reports]. Psychiatrike = Psychiatriki, 18(3), 273-6.
Andreou, C, et al. "[Neuroleptic malignant syndrome and atypical antipsychotics: two case reports]." Psychiatrike = Psychiatriki vol. 18,3 (2007): 273-6.
Andreou C, Bozikas V, Koumenis G, Garyfallos G, Giouzepas I, Fokas K. [Neuroleptic malignant syndrome and atypical antipsychotics: two case reports]. Psychiatriki. 2007 Jul;18(3):273-6. Greek, Modern. PMID: 22466631.
Copy Download .nbib Format: NLM
A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia.

Therapeutics and clinical risk management

Caccia S, Invernizzi RW, Nobili A, Pasina L.
PMID: 23966785
Ther Clin Risk Manag. 2013;9:319-28. doi: 10.2147/TCRM.S35137. Epub 2013 Aug 08.

Cariprazine is a potential antipsychotic awaiting approval from the US Food and Drug Administration. It is a dopamine D2- and D3-receptor partial agonist, with higher affinity for D3 receptors, as opposed to the D2 antagonism of most older antipsychotic...

Cite
Caccia S, Invernizzi RW, Nobili A, et al. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag. 2013;9:319-28doi: 10.2147/TCRM.S35137.
Caccia, S., Invernizzi, R. W., Nobili, A., & Pasina, L. (2013). A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Therapeutics and clinical risk management, 9319-28. https://doi.org/10.2147/TCRM.S35137
Caccia, Silvio, et al. "A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia." Therapeutics and clinical risk management vol. 9 (2013): 319-28. doi: https://doi.org/10.2147/TCRM.S35137
Caccia S, Invernizzi RW, Nobili A, Pasina L. A new generation of antipsychotics: pharmacology and clinical utility of cariprazine in schizophrenia. Ther Clin Risk Manag. 2013;9:319-28. doi: 10.2147/TCRM.S35137. Epub 2013 Aug 08. PMID: 23966785; PMCID: PMC3743638.
Copy Download .nbib Format: NLM
A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder.

Neuropsychiatric disease and treatment

Wang G, McIntyre A, Earley WR, Raines SR, Eriksson H.
PMID: 24511235
Neuropsychiatr Dis Treat. 2014 Jan 30;10:201-16. doi: 10.2147/NDT.S50248. eCollection 2014.

OBJECTIVES: To evaluate the efficacy and tolerability of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder (MDD).PATIENTS AND METHODS: This was a 10-week (8-week active treatment/2-week post-treatment) randomized, double-blind, placebo- and active-controlled study...

Cite
Wang G, McIntyre A, Earley WR, et al. A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2014;10:201-16doi: 10.2147/NDT.S50248.
Wang, G., McIntyre, A., Earley, W. R., Raines, S. R., & Eriksson, H. (2014). A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. Neuropsychiatric disease and treatment, 10201-16. https://doi.org/10.2147/NDT.S50248
Wang, Gang, et al. "A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder." Neuropsychiatric disease and treatment vol. 10 (2014): 201-16. doi: https://doi.org/10.2147/NDT.S50248
Wang G, McIntyre A, Earley WR, Raines SR, Eriksson H. A randomized, double-blind study of the efficacy and tolerability of extended-release quetiapine fumarate (quetiapine XR) monotherapy in patients with major depressive disorder. Neuropsychiatr Dis Treat. 2014 Jan 30;10:201-16. doi: 10.2147/NDT.S50248. eCollection 2014. PMID: 24511235; PMCID: PMC3916085.
Copy Download .nbib Format: NLM
Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients.

Drugs in context

Kamat SA, Offord S, Docherty J, Lin J, Eramo A, Baker RA, Gutierrez B, Karson C.
PMID: 25834621
Drugs Context. 2015 Mar 17;4. doi: 10.7573/dic.212267. eCollection 2015.

OBJECTIVE: Evaluate utilization of inpatient healthcare resources and associated costs after 12 months of treatment using long-acting injectable (LAI) antipsychotic medications among a large sample of Medicaid-insured patients categorized by different age groups.METHOD: Adult patients with schizophrenia were identified...

Cite
Kamat SA, Offord S, Docherty J, et al. Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs Context. 2015;4doi: 10.7573/dic.212267.
Kamat, S. A., Offord, S., Docherty, J., Lin, J., Eramo, A., Baker, R. A., Gutierrez, B., & Karson, C. (2015). Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs in context, 4. https://doi.org/10.7573/dic.212267
Kamat, Siddhesh A, et al. "Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients." Drugs in context vol. 4 (2015). doi: https://doi.org/10.7573/dic.212267
Kamat SA, Offord S, Docherty J, Lin J, Eramo A, Baker RA, Gutierrez B, Karson C. Reduction in inpatient resource utilization and costs associated with long-acting injectable antipsychotics across different age groups of Medicaid-insured schizophrenia patients. Drugs Context. 2015 Mar 17;4. doi: 10.7573/dic.212267. eCollection 2015. PMID: 25834621; PMCID: PMC4376094.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 356 entries